*/
Lev Gerlovin, Ezra Josephson | Life Sciences
Let’s say interchangeability is a viable regulatory option for manufacturers of biosimilars. Would it always make sense to seek an interchangeability designation from a strategic perspective? Because of the diversity and complexity of product and manufacturer characteristics, there may not be a single optimal strategy, but rather a continuum. Click below to read the article.
Gene therapy competitive dynamics: Winner takes all?
This article was originally published in Cell & Gene. It has also been published in Cell & Gene‘s sister publication, OutSourced Pharama. With many gene...